Showing 111-115 of 151 real-world data & outcomes research:
OM1 Giant Cell Arteritis Registry Reaches More Than 5,000 Patients Prospectively Followed With Deep Clinical Data

BOSTON, Dec. 8, 2020 /PRNewswire/ — OM1, a leading real-world, data, outcomes and technology company with a focus on chronic diseases, today announced the expansion of its Giant Cell Arteritis (GCA) registry. GCA, also known as temporal arteritis, is a chronic inflammatory artery disease that causes head pain, joint pain, vision problems, and fever. GCA affects approximately 230,000 Americans,[…]

Analysis of Real-Word Data in Cardiovascular Disease: Missing Data and Predictive Modeling

Tues. January 26, 2021 2:00-3:00 PM Register Real-world data (RWD) is playing an increasing role in health care decisions, especially with cardiovascular conditions such as heart failure where risk of mortality is high and comorbidities, varying symptom presentation, and disease progression drastically determine treatment pathways and outcomes. Join OM1’s Chief Medical Officer Dr. Gary Curhan[…]

RWD For Evaluating Device & Diagnostic Performance & Outcomes

October 12, 2020 – MedTech by Richard Gliklich, MD, CEO of OM1 and Michelle Leavy, MPH, Head of Health Policy at OM1 Read the full article Interest in real-world data (RWD) and real-world evidence (RWE) has increased rapidly since the passage of the 21st Century Cures Act in late 2016. Use of RWD and RWE for[…]

RWD for R&D and Market Access in Autoimmune and Chronic Diseases

Thu. Nov. 19, 2020 1:00 PM – 2:00 PM Register From accelerating clinical trials and gaining regulatory approval to expanding access and understanding market needs, this webinar will cover the basics of what makes real-world data regulatory and research grade and how it can transform your R&D and market access programs for autoimmune and other[…]

Beyond Harmonization: Implementing Standardized Outcome Measures to Support Value-Based Care

October 21, 2020- ISPOR In a recent blog post from ISPOR, Richard Gliklich, CEO of OM1 and Michelle Leavy, MPH, Head of Health Policy at OM1 detail how Implementing Standardized Outcome Measures Supports Value-Based Care. Value-based care has received significant attention in recent years as an approach to improving patient outcomes while controlling healthcare costs.[…]